Petra Pharma
Founded Year
2015Stage
Debt | AliveTotal Raised
$75.55MLast Raised
$27.55M | 5 yrs agoAbout Petra Pharma
Petra Pharma is a clinical-stage pharmaceutical company that develops a diverse portfolio of therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer.
Missing: Petra Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Petra Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Petra Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Petra Pharma is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Petra Pharma Patents
Petra Pharma has filed 6 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Rare diseases
- Autosomal recessive disorders
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/17/2020 | 11/15/2022 | Autosomal recessive disorders, Rare diseases, EC 2.7.1, Experimental cancer drugs, Neurological disorders | Grant |
Application Date | 6/17/2020 |
|---|---|
Grant Date | 11/15/2022 |
Title | |
Related Topics | Autosomal recessive disorders, Rare diseases, EC 2.7.1, Experimental cancer drugs, Neurological disorders |
Status | Grant |
Latest Petra Pharma News
May 19, 2022
Montclair, New Jersey, UNITED STATES MONTCLAIR, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180” and the “Company”), today announced that it received $12.3 million, or $1.19 per share, in cash following the close of the sale of its rights to potential future milestone payments from the acquisition of Petra Pharma Corporation by Eli Lilly and Company. “We mentioned on our recent shareholder call that the proceeds from this sale were eminent, and we are pleased to say this cash is now in 180’s account,” said Kevin M. Rendino, Chief Executive Officer of 180. “We are proud of the material progress made in reforming 180’s balance sheet since its inception in 2017. This substantial addition to 180’s permanent capital comes at an opportune time as the current market environment presents attractive investment opportunities that we believe have the potential to generate gross returns of at least 100% over a three-year period.” About 180 Degree Capital Corp. 180 Degree Capital Corp. is a publicly traded registered closed-end fund focused on investing in and providing value-added assistance through constructive activism to what we believe are substantially undervalued small, publicly traded companies that have potential for significant turnarounds. Our goal is that the result of our constructive activism leads to a reversal in direction for the share price of these investee companies, i.e., a 180-degree turn. Detailed information about 180 and its holdings can be found on its website at www.180degreecapital.com . Press Contact:
Petra Pharma Frequently Asked Questions (FAQ)
When was Petra Pharma founded?
Petra Pharma was founded in 2015.
Where is Petra Pharma's headquarters?
Petra Pharma's headquarters is located at 430 East 29th Street, New York.
What is Petra Pharma's latest funding round?
Petra Pharma's latest funding round is Debt.
How much did Petra Pharma raise?
Petra Pharma raised a total of $75.55M.
Who are the investors of Petra Pharma?
Investors of Petra Pharma include Partnership Fund for New York City, Innovate NY Fund, Eli Lilly and Company, WuXi AppTec, AbbVie Biotech Ventures and 8 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.